Mashup Score:16
OncLiveNivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma - 2 days
Mashup Score:16
Mashup Score:16
OncLiveNivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma - 2 days
Mashup Score:16
Mashup Score:14
OncLiveCombination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis - 1 week
Mashup Score:14
Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on...
Navitoclax + ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in pts w/ myelofibrosis who progressed on/ had suboptimal response with prior ruxolitinib monotherapy. @doctorpemm @MDAndersonNews #mpnsm https://t.co/i2O6nTDFpC - view on twitter
Mashup Score:12
OncLiveIs There a Role for Biomarkers in Advanced RCC? - 7 days
Mashup Score:12
Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with...
WATCH: @BraunMDPhD, of @YaleCancer, explains how biomarkers help to stratify treatment decision-making for patients with RCC. #kcsm #oncology https://t.co/8osdQxmlrb https://t.co/8osdQxmlrb - view on twitter
Mashup Score:10
OncLiveTrouble With the Curve: Beyond the Basics With Kaplan-Meier - 4 days
Mashup Score:10
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier...
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier curves. @RahulBanerjeeMD @UCSFCancer #oncology https://t.co/Bi3JRCzWnB - view on twitter
Mashup Score:6
OncLiveZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma - 1 week
Mashup Score:6
The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate...
According to the phase 1 ZN-c3-001 trial, the investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% in patients with advanced or recurrent uterine serous carcinoma. @MDAndersonNews #gyncsm https://t.co/45ZUiaEIxB https://t.co/45ZUiaEIxB - view on twitter
Mashup Score:5
OncLiveDr. Markowski on the Efficacy of Sabizabulin in Prostate Cancer - 4 days
Mashup Score:5
Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate...
WATCH: @MarkowskiGUOnc, of @hopkinskimmel, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer. #pcsm #oncology https://t.co/lfGXmWmT8a https://t.co/lfGXmWmT8a - view on twitter
Mashup Score:5
OncLiveThe FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric...
The FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric and GEJ cancer that is relapsed or refractory to approved therapies. @US_FDA #oncology https://t.co/22HUYLmux6 https://t.co/22HUYLmux6 - view on twitter
Mashup Score:5
OncLiveTargeted Treatment Arsenal for Myelofibrosis Set to Explode - 1 day
Mashup Score:5
Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment...
Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis. @mpdrc @MPNlab @mpndoc @UTHealthSAMDA @RushMedical @UCIrvineSOM @WUSTLmed #mpnsm https://t.co/NI732b57Qm - view on twitter
Mashup Score:4
OncLiveAntibody-Drug Conjugates Are Carving Out Expanded Roles Throughout Breast Cancer - 2 days
Mashup Score:4
William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each...
ADCs illustrate the continued evolution of treatment options across HER2+ breast cancer, HR+, HER2-negative breast cancer, and TNBC. @DrWGradishar @NUFeinbergMed #bcsm #oncology https://t.co/GJwPAS9R8Q https://t.co/GJwPAS9R8Q - view on twitter
Mashup Score:4
OncLiveIn a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K...
In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K inhibitors on randomized data instead of single-arm clinical trials. @US_FDA #oncology #hematology https://t.co/tRwkgx4Aht - view on twitter
The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy...
The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve pts w/ unresectable or metastatic melanoma an efficacious & tolerable immunotherapy treatment option. @HTawbi_MD @MDAndersonNews #melsm https://t.co/3QDgudPfKA - view on twitter